Abstract:Full-length p53 (p53α) plays a pivotal role in maintaining genomic integrity and preventing tumor development. Over the years, p53 was found to exist in various isoforms, which are generated through alternative splicing, alternative initiation of translation, and internal ribosome entry site. p53 isoforms, either C-terminally altered or N-terminally truncated, exhibit distinct biological roles compared to p53α, and have significant implications for tumor development and therapy resistance. Due to a lack of part and/or complete C- or N-terminal domains, ectopic expression of some p53 isoforms failed to induce expression of canonical transcriptional targets of p53α like CDKN1A or MDM2 , even though they may bind their promoters. Yet, p53 isoforms like Δ40p53α still activate subsets of targets including MDM2 and BAX . Furthermore, certain p53 isoforms transactivate even novel targets compared to p53α. More recently, non-canonical functions of p53α in DNA repair and of different isoforms in DNA replication unrelated to transcriptional activities were discovered, amplifying the potential of p53 as a master regulator of physiological and tumor suppressor functions in human cells. Both regarding canonical and non-canonical functions, alternative p53 isoforms frequently exert dominant negative effects on p53α and its partners, which is modified by the relative isoform levels. Underlying mechanisms include hetero-oligomerization, changes in subcellular localization, and aggregation. These processes ultimately influence the net activities of p53α and give rise to diverse cellular outcomes. Biological roles of p53 isoforms have implications for tumor development and cancer therapy resistance. Dysregulated expression of isoforms has been observed in various cancer types and is associated with different clinical outcomes. In conclusion, p53 isoforms have expanded our understanding of the complex regulatory network involving p53 in tumors. Unraveling the mechanisms underlying the biological roles of p53 isoforms provides new avenues for studies aiming at a better understanding of tumor development and developing therapeutic interventions to overcome resistance.

Physical and Functional Antagonism between Tumor Suppressor Protein p53 and Fortilin, an Anti-apoptotic Protein

Article Through Inhibiting STAT3 Phosphorylation and Nuclear Translocation

Abstract 675: Ninjurin1, a Target of P53, Modulates P53-Dependent Tumor Suppression in Vivo

Ninjurinl, A Target Of P53, Modulates P53-Dependent Tumor Suppression In Vivo

Fortilin reduces apoptosis in macrophages and promotes atherosclerosis.

Profilin 1 Potentiates Apoptosis Induced by Staurosporine in Cancer Cells

Expression, purification, and in vitro mitochondrial interaction analysis of full-length and truncated human tumor suppresser p53

Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance

TFIIS.h, a New Target of P53, Regulates Transcription Efficiency of Pro-Apoptotic Bax Gene

Protein interaction between p53 and Δ113p53 is required for the anti-apoptotic function of Δ113p53.

The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity

p53: A double-edged sword in tumor ferroptosis

Abstract P10: p44, the Amino-terminal Lacking Isoform of p53, is Dispensable for Tumor Suppression but Regulates Male Fertility

[Advances on Mutant P53 Research].

Mitofusin-2 is a Novel Direct Target of P53.

A Conserved Mechanism for Binding of p53 DNA-Binding Domain and Anti-Apoptotic Bcl-2 Family Proteins

Post-Translational Modifications of p53 in Ferroptosis: Novel Pharmacological Targets for Cancer Therapy

Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway

Pioneering the future of cancer therapy: Deciphering the p53-ferroptosis nexus for precision medicine